The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients ...

Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25Phase 3 CAPTIVATE trial of ...

Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...

Seismic Therapeutic, Inc., the machine learning immunology company, today announced the dosing of the first healthy subject ...

antibodies. Higher Quantitative Myasthenia Gravis-Revised (QMG) scores, indicating more severe disease based on clinician ratings, have been associated with frequent exacerbations. New data from ...

Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has received a consensus recommendation of “Buy” from the nine ...

Approval in Myasthenia gravis in key markets could eventually ... label study which found benefits for patients with anti-AchR antibody-positive gMG who had previously failed immunosuppressive ...

HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing ...

Guggenheim reiterated their buy rating on shares of Immunovant (NASDAQ:IMVT – Free Report) in a report issued on Monday ...

A MAN in Bromsgrove with a rare autoimmune disease has welcomed news of an historic medical milestone which has seen blood ...

UCB also notes that unlike monoclonal antibody C5 inhibitors Zilbrysq ... president and chief executive of the Myasthenia Gravis Foundation of America. “This is an important development for ...